- Home
- AMRC vs SLS Comparison
AMRC vs SLS Comparison
Compare AMRC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRC | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 924.5M |
| IPO Year | 2010 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AMRC | SLS |
|---|---|---|
| Price | $25.65 | $12.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $37.88 | $10.00 |
| AVG Volume (30 Days) | 640.3K | ★ 6.3M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | N/A |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | $9.07 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.38 | $1.39 |
| 52 Week High | $44.93 | $15.88 |
Technical Indicators
Market Signals| Indicator | AMRC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 52.09 |
| Support Level | $24.73 | $3.91 |
| Resistance Level | $33.03 | $15.88 |
| Average True Range (ATR) | 1.86 | 1.07 |
| MACD | 0.71 | -0.11 |
| Stochastic Oscillator | 52.93 | 57.18 |
Price Performance
Historical ComparisonAbout AMRC Ameresco Inc.
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.